Our focus is on diseases of the central nervous system, including rare diseases.

Our aim is to pursue validated drug tergets and lead molecules, finalizing small molecule candidates for therapeutic intervention.

Our Company Strategy is to:
• In-license gene data, targets and molecules from Universities, Research Institutions and Private Companies
• Perform Drug discovery process from target to POC (Phase IIa);
• Out-license molecules at different levels of development;
• Set up alliances with Pharma/Biotech Companies for joint R & D process;
• Effectively study drugs for orphan indications.